Immunomodulatory and Therapeutic Properties of Bestatin in Mice

James E. Talmadge, Barbara F. Lenz, Robin Pennington, Hamblin Phillips, Mark Schneider, Henry Tribble

Research output: Contribution to journalArticle

81 Scopus citations

Abstract

In this report, we describe the immunomodulatory properties and therapeutic efficacy of bestatin. Macrophage activation, but not natural killer cell augmentation, was observed both in vitro and in vivo. Immunostimulation of T-cell activity was observed in assays of allogeneic mixed lymphocyte response, but cytotoxic effector cells did not develop after an allogeneic mixed lymphocyte-tumor cell culture. Bestatin also had T-cell adjuvant activity when it was admixed with a suboptimal vaccine composed of irradiated tumor cells. We observed significant therapeutic activity against preexisting experimental and spontaneous metastases when bestatin was administered at high doses per animal for 4 weeks.

Original languageEnglish (US)
Pages (from-to)4505-4510
Number of pages6
JournalCancer Research
Volume46
Issue number9
StatePublished - Sep 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunomodulatory and Therapeutic Properties of Bestatin in Mice'. Together they form a unique fingerprint.

  • Cite this

    Talmadge, J. E., Lenz, B. F., Pennington, R., Phillips, H., Schneider, M., & Tribble, H. (1986). Immunomodulatory and Therapeutic Properties of Bestatin in Mice. Cancer Research, 46(9), 4505-4510.